JAMES F. C. ROW

THE UNIVERSITY OF WISCONSIN Laboratory of Genetics Genetics Building MADISON, WISCONSIN 53706

Department of Genetics College of Agriculture

Department of Medical Genetics
School of Medicine

September 1

Dear Josh:

If you haven't already done such a column (I have only seen two), how about one on ethical and scientific problems arising in research on human subjects. I would like to see what you would do with the dilemma of the necessity of keeping the path subject somewhat in the dark (as with placebos) while at the same time complying with a moral obligation to keep him as fully informed as possible. I could imagine that in some kinds of experiments the fact that a person is told that he is receiving either a drug or a plecebo might create a bias. Whether there is such an example I don't know, but the general issue is: Is an investigator ever justified in withbolding information from a subject?

Best wishes.

(im

Dear Jim-- I have been thinking of this for some time, esepcially since Beecher's stringent and widely publicized comments. (I am also on Clinical Research Center Policy Committee at the school here). In controlled trials, patients must be told they are in the experiment, but not whether as individuals they are receiving the drug or a placebo. Is this a great difficulty? Of course when a dubious new drug is being contrasted with some established procedure, there is a real problem.

I guess I am also deeply exercised about the fruitless risks to which patients are exposed, even with their consent, in experiments so poorly designed they can tell nothing--- which is all too typical!

dent 1/13/66